FDA deined approval for a new weight-loss drug: Qnexa

October 29th, 2010

In July, an advisory committee to the FDA voted against approval of the Qnexa, a new weight-loss prescription drug. Qnexa is a combination of two pre-existing drugs: phentermine and topiramate. Concerns have been raised about whether the medication can cause birth defects, heart attack and stroke.

Vivus Inc., the drug developer last month “released data from a two-year study of 4,323 patients showing there was no increased risk of cardiovascular events in people taking the medication compared with people taking a placebo.”

Goes here for more information on Qnexa.